Skip to main content
search
Poster

Development of a human PBMC TXG-MAPr as a mechanistic framework to interpret toxicodynamic variability across the human population

Skip to PDF content

Authors: Natasha Tahir1 , I. B. Bruns1 , L. van Schijndel2 , J. Rousel2 , D. R. Pereira2 , M. Moerland 2 , S. Fu 3 , N. Quignot 3 , F. Y. Bois 3 , M. J. Moné 1 , G. Callegaro 1 , S. Le Dévédec1 , M. Niemeijer1 , J. L. Dorne4 , G. E.N. Kass4 , and B. van de Water

Your partner in drug development

Certara’s Toxicology Services combine unmatched expertise, proven methodologies, and collaborative solutions to help you navigate the complexities of nonclinical drug development.

Explore Toxicology Services

You May Also Like

Characterization of human toxicodynamic variability using peripheral blood mononuclear cells from a large cohort of healthy volunteers
Characterization of human toxicodynamic variability using peripheral blood mononuclear cells from a large cohort of healthy volunteersPoster

Characterization of human toxicodynamic variability using peripheral blood mononuclear cells from a large cohort of healthy volunteers

Certara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Development
Certara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate DevelopmentAnnouncement

Certara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Development

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies
Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal AntibodiesPoster

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies